Drug Profile
Research programme: antibody therapeutics - argenx/Bayer
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator arGEN-X; Bayer
- Developer argenx; Bayer
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Undefined in Germany (Parenteral)
- 28 Jun 2018 No recent reports of development identified for research development in Undefined in Netherlands (Parenteral)
- 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System Technology from Lonza